|
Session 117
Poster Abstracts
Drug Resistance following First-Line ART
Monday, 1 - 4 pm
Poster Hall |
661
 |
Emerging ART Drug Resistance in Subtype C: Experience from the 2 Clinics in Johannesburg, South Africa
Carole L Wallis*1, C Bell1, R Boulme2, I Sanne1, F Venter1, M Papathanasopoulos1, and W Stevens3
1Univ of the Witwatersrand, Johannesburg, South Africa; 2ABL SA/TherapyEdge Inc, Luxembourg, Belgium; and 3Natl Hlth Lab Svc, Johannesburg, South Africa |
| 662 |
Development of Drug Resistance in a Sub-Saharan Cohort of HIV 1-infected Adult Patients Receiving Fixed-dose Combination of Stavudine + Lamivudine + Nevirapine as Standard First-line Regimen
A G Marcelin1,2, A G Marcelin1,2, B Jarrousse3, M Ba4, M Dakouo5, A Doumbia6, I Haidara6, G Brucker1,2, G Brucker1,2, G Carcelain1,2, G Carcelain1,2, C Katlama1,2, C Katlama1,2, Vincent Calvez*1,2, Vincent Calvez*1,2, and SOLTHIS Triomune study group
1Ctr Hosp Univ Pitie-Salpetriere, Paris, France; 2SOLTHIS, Paris, France; 3SOLTHIS, Ségou, Mali; 4ONG Walé, Ségou, Mali; 5ONG APROFEM, Ségou, Mali; and 6Hosp Regional, Segou, Mali |
| 663 |
Tenofovir Resistance among HIV-infected Patients Failing a Fixed-dose Combination of Stavudine + Lamivudine + Nevirapine in a Resource-limited Setting
Somnuek Sungkanuparph*1, W Manosuthi2, S Kiertiburanakul1, B Piyavong1, and W Chantratitra1
1Faculty of Med, Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand and 2Bamrasnaradura Inst, Ministry of Publ Hlth, Nonthaburi, Thailand |
664
|
The 67N 70R 215Y TAM Pathway in HIV-1 Subtype C Infection Treated with ZDV/ddI-containing HAART in Southern Africa
Vlad Novitsky*1, C Wester2, V DeGruttola1, H Bussmann2, S Gaseitsiwe2, S Moyo2, R Musonda2, E Widenfelt2, R Marlink1, and M Essex1
1Harvard Sch of Publ Hlth, Boston, MA, US and 2Botswana-Harvard Sch of Publ Hlth AIDS Initiative Partnership, Gaborone |
| 665 |
Baseline Resistance to NNRTI as a Predictor of Virologic Failure in Treatment-naïve Subjects Receiving Efavirenz-based Regimens in ACTG A5095
Daniel Kuritzkes*1,2, Daniel Kuritzkes*1,2, C Lalama3, H Ribaudo3, M Marcial1, W Meyer4, C Shikuma5, K Klingman6, B Schackman7, E Acosta8, R Gulick7, and the ACTG A5095 Protocol Team
1Brigham and Women's Hosp, Boston, MA, US; 2Harvard Med Sch, Boston, MA, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Quest Diagnostics, Inc, Baltimore, MD, US; 5Univ of Hawaii, Honolulu, US; 6Div of AIDS, NIAID, NIH, Bethesda, MD, US; 7Weill Med Coll of Cornell Univ, New York, NY, US; and 8Univ of Alabama at Birmingham, US |
| 666 |
Transmission of HIV-1 Minority Resistant Variants and Response to First-line ART
O Peuchant1, R Thiébaut2, S Capdepont1, V Lavignolle-Aurillac2, D Neau1,2, D Neau1,2, P Morlat1, F Dabis2, H Fleury1, Bernard Masquelier*1, and the ANRS CO3 Aquitaine Cohort
1Bordeaux Univ Hosp, Univ Victor Segalen, France and 2INSERM U593 and E0338, Bordeaux, France |
| 667 |
Emergence of Drug Resistance on First-line Combination Therapy in the Swiss HIV Cohort Study: A Comparison between Boosted PI and NNRTI
V von Wyl1, S Yerly2, J Böni3, J Schüpbach3, P Burgisser4, T Klimkait5, M Rickenbach6, L Perrin2, B Ledergerber1, Huldrych Günthard*1, and the Swiss HIV Cohort Study (SHCS)
1Univ Hosp, Zurich, Switzerland; 2Geneva Univ Hosp, Switzerland; 3Univ of Zurich, Switzerland; 4Lausanne Univ Hosp, Switzerland; 5Univ of Basel, Switzerland; and 6Swiss HIV Cohort Study Data Ctr, Lausanne |
|
